Amgen kept at neutral by Merrill

Merrill Lynch analyst Eric Ende maintained Amgen Inc. at neutral. The analyst believes revised third-quarter Street projections for Amgen's cancer supportive care drugs are too high, particularly Aranesp. Merrill estimates that 72% of the second-quarter growth in the U.S. franchise came from two extra selling days rather than actual product demand. Fewer selling days in the third-quarter could bring sales down to below current expectations. Shares of the Thousand Oaks, Calif.-based pharmaceutical company were down 21 cents, or 0.30%, at $69.07 on volume of 7,179,019 shares versus the three-month running average of 8,603,240 shares. (Nasdaq: AMGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.